Summary
• 60 Degrees Pharmaceuticals, Inc. (SXTP) shares rose 6.67% to $0.5899 in after-hours trading following positive study results.
• A study revealed that 24% of patients with chronic fatigue tested positive for Babesia infection, suggesting new research avenues for treatment.
• The stock has declined approximately 91.4% year-to-date, with trading activity remaining subdued compared to historical averages.
The stock of 60 Degrees Pharmaceuticals, Inc. (SXTP) rose to $0.5899 in after-hours trading, reflecting a gain of 6.67% from the last closing price of $0.553. This movement comes amid news of a significant discovery in a recent study, fueling investor interest in the company.
Positive Study Results on Babesia Infection
On December 29, 2025, 60 Degrees Pharmaceuticals announced the results of a peer-reviewed study conducted at North Carolina State University. The research indicated that Babesia infection was detected in 24% of patients presenting with chronic fatigue, supporting the potential for further investigations into chronic babesiosis and the evaluation of the company’s ARAKODA® treatment. This finding has garnered attention as it opens new avenues for understanding and treating chronic fatigue syndromes related to infectious agents.
Trading Metrics and Performance Overview
Despite the recent uptick, the stock has faced considerable downward pressure over the past year, with a year-to-date performance decline of approximately 91.4%. The 10-day average volume stands at around 259,397 shares, while the average volume over three months is about 152,258 shares. The recent volume of 12,950 shares suggests that trading activity is relatively quiet compared to these averages, indicating a cautious approach among investors.
The company’s trading indicators reflect significant volatility, with a 52-week high noted at a -93.09% decline from its peak price, alongside an RSI of 18.19, signaling that the stock may be in oversold territory.
Outlook and Moving Forward
With the latest findings related to Babesia infections making headlines, investors are likely to closely monitor how this information may affect the company’s future studies and market positioning. The stock has potential for volatility as traders evaluate the implications of the study results on the business development and growth prospects of 60 Degrees Pharmaceuticals.
The after-hours reaction highlights renewed attention on the company’s fundamentals as traders assess the implications of the latest disclosure.